# Potential of green tea extract to suppress colorectal polyp development in patients with familial adenomatous polyposis: a double-blind, randomized controlled trial Japan Familial Adenomatous Polyposis Prevention Study (J-FAPP Study I)

**Authors:** Hideki Ishikawa, Michihiro Mutoh, Tetsuro Yamane, Keiji Wakabayashi, Keiji Hirata, Takeo Iwama, Tomiyo Nakamura, Naohiro Tomita, Yutaka Matsuyama

PMC · DOI: 10.1186/s41021-026-00354-2 · Genes and Environment · 2026-03-02

## TL;DR

This study tested green tea extract's ability to reduce colorectal polyps in patients with a genetic condition that causes many polyps and increases cancer risk.

## Contribution

The study is the first double-blind, randomized controlled trial to evaluate green tea extract in familial adenomatous polyposis patients.

## Key findings

- Green tea extract showed a trend toward reducing polyp enlargement, though the result was not statistically significant.
- Few adverse events were observed, suggesting green tea extract is well-tolerated.
- The study suggests a potential for green tea extract to be a preventive treatment, warranting larger trials.

## Abstract

Familial adenomatous polyposis (FAP) is an autosomal dominantly inherited disease that results in the development of more than 100 polyps, premalignant lesions, in the colorectum. Therefore, patients with FAP are a high-risk group for colorectal cancer (CRC). The only standard method of preventing CRC is total colectomy. Thus, alternative methods to prevent the development of CRC are desired by patients. Epidemiological and animal studies suggested that green tea and its extracts, such as (−)-epigallocatechin gallate, may have the potential to prevent cancer development.

In the present study, we evaluated the suppressive effects of green tea extract (GTE) on suppress colorectal polyps in FAP and conducted a double-blind clinical trial. Eighty patients were randomly assigned to the GTE group (1.5 g/day for 2 years) and an equal number were assigned to the placebo group. The primary endpoint of colon polyp enlargement tended to be reduced in the GTE group compared with the placebo group, with a risk ratio of 0.43 (95% confidence interval 0.12–1.49; p = 0.16).

Given that the risk ratio was less than 0.5 and few adverse events were observed, we believe that further research using GTE after calculating the necessary sample size is calculated on the based of this study, should be considered in a future large-scale clinical trial.

## Linked entities

- **Chemicals:** (−)-epigallocatechin gallate (PubChem CID 1287)
- **Diseases:** colorectal cancer (MONDO:0005575), familial adenomatous polyposis (MONDO:0021055)

## Full-text entities

- **Genes:** APC (APC regulator of Wnt signaling pathway) [NCBI Gene 324] {aka BTPS2, DESMD, DP2, DP2.5, DP3, GS}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}
- **Diseases:** autosomal dominantly inherited disease (MESH:D030342), colon tumors (MESH:D003110), Hereditary Tumors (MESH:D013132), premalignant lesions (MESH:D009059), GTE (OMIM:614156), bleeding (MESH:D006470), colon polyp (MESH:D003111), hematemesis (MESH:D006396), carcinogenesis (MESH:D063646), adenomas (MESH:D000236), Cancer (MESH:D009369), adenomas and carcinomas (MESH:D000230), rectal cancer (MESH:D012004), rectal adenoma (MESH:D012002), IDP (MESH:C000657744), intestinal tumors (MESH:D007414), Adult Disease (MESH:C538052), polyp (MESH:D011127), gastrointestinal cancers (MESH:D005770), gastrointestinal mucosal damage (MESH:D005767), sudden death (MESH:D003645), cardiovascular toxicity (MESH:D002318), FAP (MESH:D011125), anemia (MESH:D000740), ascites (MESH:D001201), CRC (MESH:D015179)
- **Chemicals:** vitamin C (MESH:D001205), (-)-epicatechin gallate (MESH:C062669), sulindac (MESH:D013467), 8-OHdG (MESH:D000080242), N-ethyl-N'-nitro-N-nitrosoguanidine (MESH:C013525), aspirin (MESH:D001241), (-)-epicatechin (MESH:D002392), lactate (MESH:D019344), lactose (MESH:D007785), green (MESH:C024537), (+)-epigallocatechin gallate (MESH:C045651), azoxymethane (MESH:D001397), gallic acid (MESH:D005707), dietary fiber (MESH:D004043), (+)-gallocatechin (MESH:C057580), alcohol (MESH:D000438), polyphenols (MESH:D059808), (-)-catechin gallate (MESH:C417939), (-)-gallocatechin gallate (MESH:C417940), N-methyl-N-nitrosourea (MESH:D008770), Indigo carmine dye (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12958651/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12958651/full.md

---
Source: https://tomesphere.com/paper/PMC12958651